XNAS
SPRC
Market cap2mUSD
Apr 10, Last price
0.27USD
1D
-0.62%
1Q
-66.40%
IPO
-99.85%
Name
Scisparc Ltd
Chart & Performance
P/E
—
P/S
1.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-44.81%
Rev. gr., 5y
28.00%
Revenues
3m
+113.73%
Net income
-5m
L+97.61%
CFO
-6m
L-25.64%
Profile
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2,879 113.73% | 1,347 26.01% | |||||||
Cost of revenue | 8,652 | 8,664 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,773) | (7,317) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 22 | 14 | |||||||
Tax Rate | |||||||||
NOPAT | (5,795) | (7,331) | |||||||
Net income | (5,122) 97.61% | (2,592) -55.32% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,552 | 9,005 | |||||||
BB yield | -278.85% | -260.53% | |||||||
| Debt | |||||||||
Debt current | 52 | 27 | |||||||
Long-term debt | 100 | 27 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,226 | ||||||||
Net debt | (6,364) | (4,841) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (5,887) | (7,917) | |||||||
CAPEX | (4,869) | ||||||||
Cash from investing activities | (1,109) | (7,084) | |||||||
Cash from financing activities | 5,498 | 11,700 | |||||||
FCF | (5,846) | (5,618) | |||||||
| Balance | |||||||||
Cash | 5,076 | 3,574 | |||||||
Long term investments | 1,440 | 1,321 | |||||||
Excess cash | 6,372 | 4,828 | |||||||
Stockholders' equity | 9,587 | (4,480) | |||||||
Invested Capital | 3,291 | 10,956 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 408 | 176 | |||||||
Price | 4.88 -75.16% | 19.64 -87.87% | |||||||
Market cap | 1,991 -42.40% | 3,456 -72.92% | |||||||
EV | (2,400) | (1,385) | |||||||
EBITDA | (5,235) | (7,130) | |||||||
EV/EBITDA | 0.46 | 0.19 | |||||||
Interest | 36 | ||||||||
Interest/NOPBT | |||||||||